| Treatment groups (mg) > |
0 mg |
50 mg |
100 mg |
150 mg |
NSNC |
SNC |
VNSNC |
| Total WBC (103/µL) |
4.0 ± 0.2 |
5.4 ± 0.2 |
1.8 ± 0.1 |
2.6 ± 0.4 |
9.4 ± 0.1 |
21.0 ± 0.1 |
6.6 ± 0.0 |
| Heterophil (%) |
22 |
17 |
15 |
14 |
24 |
31 |
27 |
| Lymphocyte (%) |
70 |
74 |
80 |
81 |
65 |
62 |
69 |
| H/L ratio |
0.31 |
0.23 |
0.19 |
0.17 |
0.37 |
0.5 |
0.39 |
| Monocytes (%) |
5 |
6 |
2 |
2 |
4 |
4 |
1 |
| Basophil (%) |
2 |
3 |
2 |
3 |
3 |
3 |
3 |
| Eosinophil (%) |
1 |
0 |
1 |
0 |
1 |
0 |
0 |
| Hb (g/dl) |
9.7 |
10.2 |
9.8 |
9.4 |
10.1 |
9.8 |
11.1 |
| PCV (%) |
29 |
30 |
29 |
28 |
30 |
29 |
33 |
| Plasma cell |
- |
+ |
+ |
+ |
- |
- |
- |
NSNC: Not Supplemented Not Challenged; SNC: Supplemented but Not Challenged; NSC: Not Supplemented but Challenged; VNSNC: NDV Vaccinated Not Supplemented Not Challenged |
